ImmunityBio (NASDAQ:IBRX) Receives “Buy” Rating from D. Boral Capital

ImmunityBio (NASDAQ:IBRX)‘s stock had its “buy” rating reissued by analysts at D. Boral Capital in a research report issued on Thursday,Benzinga reports. They currently have a $30.00 price objective on the stock. D. Boral Capital’s target price points to a potential upside of 488.24% from the stock’s previous close.

Several other equities analysts have also commented on IBRX. EF Hutton Acquisition Co. I raised shares of ImmunityBio to a “strong-buy” rating in a research report on Wednesday, October 23rd. Piper Sandler lowered their price objective on shares of ImmunityBio from $6.00 to $4.75 and set a “neutral” rating for the company in a research note on Monday, August 19th.

ImmunityBio Price Performance

Shares of IBRX stock opened at $5.10 on Thursday. The company has a market cap of $3.55 billion, a price-to-earnings ratio of -5.54 and a beta of 0.99. The stock’s fifty day moving average price is $4.27 and its 200 day moving average price is $5.15. ImmunityBio has a 1-year low of $3.10 and a 1-year high of $10.53.

Institutional Investors Weigh In On ImmunityBio

A number of large investors have recently bought and sold shares of IBRX. Captrust Financial Advisors acquired a new stake in ImmunityBio during the 3rd quarter valued at approximately $41,000. Lazard Asset Management LLC lifted its position in ImmunityBio by 102.6% during the first quarter. Lazard Asset Management LLC now owns 13,019 shares of the company’s stock valued at $68,000 after purchasing an additional 6,593 shares during the period. Algert Global LLC acquired a new position in ImmunityBio during the second quarter valued at $86,000. Virtu Financial LLC purchased a new stake in ImmunityBio in the third quarter valued at $51,000. Finally, Axxcess Wealth Management LLC acquired a new stake in ImmunityBio during the 1st quarter worth about $85,000. Hedge funds and other institutional investors own 8.58% of the company’s stock.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.